Eli Lilly Breaks Ground on $6.5 Billion Houston Plant as Foundayo Wins 1 in 3 New U.S. Starts
Updated
Updated · Yahoo Finance · Sep 21
Eli Lilly Breaks Ground on $6.5 Billion Houston Plant as Foundayo Wins 1 in 3 New U.S. Starts
3 articles · Updated · Yahoo Finance · Sep 21
Summary
Houston will host Eli Lilly’s new $6.5 billion manufacturing site, with the Generation Park facility slated to begin operating by 2030.
Dave Ricks said Foundayo now accounts for one in three new U.S. oral weight-loss drug starts, and Lilly expects July’s Medicare obesity-drug coverage to accelerate uptake.
Foundayo entered the U.S. market in April and generated $98 million in second-quarter revenue, while Lilly plans additional country launches later this year.
The plant will make core chemical ingredients for medicines across cardiometabolic health, oncology, immunology and neuroscience, extending Lilly’s manufacturing buildout.
Lilly says it has committed more than $50 billion to manufacturing since 2020, as it presses its lead over Novo Nordisk in obesity and diabetes treatments.
With Lilly pouring billions into manufacturing, could a hidden rival disrupt their oral weight-loss empire before the 2030 mega-plant even opens?
As patients trade injections for daily pills, will the convenience of Foundayo create a lifelong, costly dependency on pharmaceutical weight management?